Publications
76
Citations
2,826
Est. group size
~33
Recurring co-author estimate
Active years
20
Publishing since 2007
Typically publishes in teams of ~6 · 32% small-team papers (≤3 authors) · across 19 venues
- Abstract 1766: Dual EGFR and Bcl-2 inhibition overcomes resistance in sinonasal squamous cell carcinoma
Cancer Research · 2026
- ACR Appropriateness Criteria® Lung Cancer-Surveillance After Therapy
Journal of the American College of Radiology · 2025
- Assessing the Tumor Immune Landscape Across Multiple Spatial Scales to Differentiate Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer
Laboratory Investigation · 2024
- 154P Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 antagonistic antibody, as monotherapy in treatment-refractory non-small cell lung cancer (NSCLC)
Immuno-Oncology Technology · 2024
- The Relationship between Hand Dexterity with Hand Grip Strength in Young Males
Indian Journal of Physiotherapy and Occupational Therapy - An International Journal · 2023
- 122P Casdozokitug (casdozo, SRF388), a first-in-class IL-27 targeting antibody, as monotherapy (monotx) or in combination with pembrolizumab (pembro) in treatment-refractory non-small cell lung cancer (NSCLC)
Immuno-Oncology Technology · 2023
- EP13.07-01 Understanding Real-Life Response to Lurbinectedin as Second Line Therapy in Patients with Extensive Stage Small-Cell Lung Cancer
Journal of Thoracic Oncology · 2023
- Non‐Small Cell Lung Cancer: Stages II and III
2023
- Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer
Scientific Reports · 2022
- An evaluation of sotorasib for the treatment of patients with non–small cell lung cancer with KRASG12C mutations
Expert Opinion on Pharmacotherapy · 2022
- Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer
Frontiers in Immunology · 2022
- The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): Initial results.
Journal of Clinical Oncology · 2022
- First-in-human study of pelcitoclax (APG-1252) in combination with paclitaxel in patients (pts) with relapsed/refractory small-cell lung cancer (R/R SCLC).
Journal of Clinical Oncology · 2022
- Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity
Cancer Cell · 2021
- Trial in progress: A multicenter phase Ib/II study of pelcitoclax (APG-1252) in combination with paclitaxel in patients with relapsed/refractory small-cell lung cancer (R/R SCLC).
Journal of Clinical Oncology · 2021
- Journal of Clinical Oncology×11
- Journal of Thoracic Oncology×10
- Cancer Research×7
- International Journal of Radiation Oncology*Biology*Physics×4
- Scientific Reports×3
- Hossein Borghaei
Medicine · The Ohio State University
- David P. Carbone
Medicine · The Ohio State University
- Gregory A. Otterson
Medicine · The Ohio State University
- Erin M. Bertino
Medicine · The Ohio State University
- Bryan J. Schneider
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile